圣诺生物：本次计提相应减少公司2025年前三季度合并利润总额约564万元

Group 1 - The core point of the article is that Shengnuo Bio announced a reduction in its consolidated profit for the first three quarters of 2025 by approximately 5.64 million yuan, which is subject to final confirmation by the auditing firm [1] - Shengnuo Bio's revenue composition for the year 2024 indicates that 98.91% of its revenue comes from the pharmaceutical manufacturing industry, while other businesses account for 1.09% [1] - As of the report, Shengnuo Bio has a market capitalization of 6.5 billion yuan [1]